Why Was Exagen Stock Up on Aug 5, 2026?

Exagen posted record Q2 2026 revenue of $19.94 million, up 16% year over year and above the $17.80 million estimate. Adjusted EBITDA loss narrowed sharply to just $0.1 million, from $1.7 million in the same quarter a year earlier. Shares rose 19.403% on the day.

A near-breakeven quarter, not just a beat

The adjusted EBITDA loss narrowing from $1.7 million to $0.1 million year over year is the number that separates this from an ordinary revenue beat — Exagen is now within a rounding error of operating breakeven, a genuine inflection point for a small-cap diagnostics company that has run at a loss. Management raised full-year 2026 revenue guidance to $72-75 million from a prior $70-73 million range, coming in slightly above the $71.6 million analyst consensus.

Two separate levers, not one

The raise rests on two distinct, independently moving parts. First, pricing power on the company's core AVISE CTD autoimmune diagnostic test: the trailing-twelve-month average selling price rose 4% to $446 per test, up $18. Second, a genuinely new revenue line — pharma services revenue crossed $1 million in quarterly revenue for the first time, validating the company's data and biobank capabilities to drug developers as a standalone business line rather than a side project. A guidance raise built on an existing product's pricing power plus a new revenue line clearing its first real threshold is a broader base than a raise resting on one segment alone.

What to watch

Pharma services revenue in the next two quarters is the number that confirms whether crossing $1 million was a one-off or the start of a real second revenue line — that distinction is what turns this quarter's near-breakeven result into a sustained trend.